The administration of trastuzumab concomitantly with chemotherapy was discovered to enhance the survival rate of patients afflicted with metastatic breast cancer that is positive for HER2 in 2001, and following that, trastuzumab improved outcomes in HER2-positive early-stage breast cancer in the adjuvant setting in 2005 [8,9]. Here, ERBB2 is linked to breast carcinoma.